

**COPY OF PAPERS
ORIGINALLY FILED**

**REQUEST FOR CONTINUED EXAMINATION
(RCE) TRANSMITTAL**

Subsection (b) of 35 U.S.C. § 132, effective on May 29, 2000, provides for continued examination of an utility or plant application filed on or after June 8, 1995.

of the **Armed Forces (Amendment) Protection Act of 1999 (AIPA)**.

Application No.: 09/787,256
Filing Date: March 15, 2001
First Named Inventor: Hayes, et al.
Group Art Unit: 1625
Examiner: Bernard L. Dentz
Attorney Docket No.: P32147

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE WITH SUFFICIENT POSTAGE AS FIRST-CLASS MAIL IN AN ENVELOPE ADDRESSED TO: ASSISTANT COMMISSIONER FOR PATENTS, BOX RCE, WASHINGTON, D.C. 20231.

NAME:

DATE: SEPT. 6, 2002

This is a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 of the above-identified application. **NOTE:** 37 C.F.R. § 1.114 is effective on May 29, 2000. If the above-identified application was filed prior to May 29, 2000, applicant may wish to consider filing a continued prosecution application (CPA) under 37 C.F.R. § 1.53 (d) (PTO/SB/29) instead of RCE to be eligible for the patent term adjustment provisions of the AIPA. See Changes to Application Examination and Provisional Application Practice, Final Rule, 65 Fed. Reg. 5003 (Mar. 24, 2000); Interim Rule, 65 Fed. Reg. 14865 (Mar. 20, 2000) 1233 Off. Gaz. Pat. Office 47 (April 11, 2000), which established RCE practice.

1. Submission required under 37 C.F.R. § 1.114

a. Previously submitted

i. Consider the amendment(s)/reply under 37 C.F.R. § 1.116 previously filed on _____
(Any unnumbered amendment(s) referred to above will be entered)

ii. Consider the arguments in the Appeal Brief or Reply Brief previously filed on _____

iii. Other _____

b. Enclosed

- i. Amendment/Reply _____ pages
- ii. Affidavit(s)/Declaration(s) _____ pages
- iii. Information Disclosure Statement (IDS) _____ 1 pages
- iv. Form PTO 1449 _____ 1 pg. & _____ 1 Reference and 1 to
- v. Return Receipt Postcard (MPEP 503) (specifically itemized)
- vi. Other _____

2. *Micrilarvacei*

a. Suspension of action on the above-identified application is requested under 37 C.F.R. § 1.103 (c) for a period of _____ months. (Period of suspension shall not exceed 3 months; Fee under 37 C.F.R. § 1.17(l) required)

b. Other _____

3 FEEFS

a. The Director is hereby authorized to charge the following fees or credit any overpayments, to
Deposit Account No. 19-2570.

General Authorization to charge any and all fees under 37 CFR 1.136(a)(3)) relating to this application.

i. RCB fee required under 37 C.F.R. § 1.17(e). \$740.00
ii. (Q) Month Extension of time fee (37 C.F.R. §§ 1.136 and 1.17) \$0.00
iii. Additional Fees
iv. Total Fee to be charged to Deposit Account 19-2570 \$740.00

CORRESPONDENCE ADDRESS

R E S P E C T F U L L Y S U B M I T T E D.

Address: GLAXOSMITHKLINE
GlaxoSmithKline Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
(610) 270-4877 Facsimile (610) 270-5090

Signature Loretta J. Henderson
NAME Loretta J. Henderson

Registration No. 37,347